Three experts discussed recent notable research of interest to rheumatology professionals across a range of topics.
The ACR Revamps RISE Registry into a Productivity & Learning Tool
The ACR’s new RISE Registry, set for 2026, will be a modern productivity tool with new analytics, easy EHR connection & robust research data.
Incomplete Penetrance in Autoinflammatory Diseases
At this ACR Convergence 2025 session, immunologist Dusan Bogunovic, PhD, discussed his team’s research into how genetic immune diseases manifest with different phenotypes in different people.
Rheumatology Celebrates Key Milestones
The Association for Rheumatology Professionals (ARP) celebrates 60 years & the Rheumatology Research Foundation marks 40 years of advancing patient care & research.
Rheumatology Research Foundation Launches $1 Million Emergency Fund to Safeguard Innovation
In the wake of unprecedented federal research cuts, the new $1 million emergency funding commitment aims to protect vital projects and the future of patient care.
How AI Can Make Clinical Rheumatology Research More Efficient & Fruitful
A rheumatologist with a background in biostatistics, data science & bioinformatics discusses the use of artificial intelligence in clinical research.
Patients’ Voices Ring Out
Research & patients reap benefits when patients with rheumatic conditions get involved in patient-facing organizations & in clinical research planning.
CAR-T Cell Therapy in Autoimmune Disease: The Next Frontier
Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.
Changes in the Rheumatology Workforce
Mannion et al. set out to describe the adult rheumatology workforce in the U.S. by measuring the number of rheumatologists and advanced practice providers entering and exiting the field and studying their demographics.
Calprotectin Shows Promise as APS Thrombocytopenia Biomarker
Hoy et al. sought to evaluate the presence, clinical associations, and potential mechanistic roles of circulating calprotectin in a cohort of patients with primary antiphospholipid syndrome (APS) and those with antiphospholipid antibodies. Calprotectin levels were higher in patients with primary APS and those with antiphospholipid antibodies than in healthy controls. These data suggest that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS-related thrombocytopenia.
- 1
- 2
- 3
- …
- 78
- Next Page »